Novartis receives FDA approval for Egaten for the treatment of fascioliasis, a neglected tropical disease - Seite 2
Novartis has been donating Egaten to the WHO since 2005, helping to treat around 2 million fascioliasis patients in more than 30 countries. In 2018, we renewed our agreement with the WHO to extend the drug donation until 2022, expected to reach 300 000 patients per year.
"This FDA decision is welcome news for millions who suffer or are at risk of fascioliasis and removes a major hurdle in expanding treatment to countries where it is most needed," said Dr Mwelecela Malecela, Director of the Department of Control of Neglected Tropical Diseases at the WHO. "We are thankful to Novartis for their sustained decade-long commitment in tackling yet another disease of poverty."
The Novartis commitment to neglected tropical diseases
Novartis is a signatory to the London Declaration on Neglected Tropical Diseases, which aims to control, eliminate or eradicate 10 diseases by 2020. The Novartis Institute for Tropical Diseases,
founded in 2001, is dedicated to finding new medicines to treat neglected diseases. In addition to malaria, research currently focuses on parasitic diseases such as cryptosporidiosis (diarrheal
disease) and three major kinetoplastid diseases: human African trypanosomiasis (sleeping sickness), Chagas disease and leishmaniasis. Building on our experience in neglected diseases,
Novartis also implements programs to target access to medicine for chronic diseases and, most recently, to address sickle cell disease in Africa, starting in Ghana.
About fascioliasis
Fascioliasis is caused by two species of parasitic flatworms or trematodes that mainly affect the liver (Fasciola hepatica or Fasciola gigantica). Both
species can infect humans following ingestion of larvae in contaminated water or food (mainly raw or undercooked vegetation). The larvae mature into adult worms in the biliary tract. No continent
is free from fascioliasis; human cases have been reported from more than 70 countries worldwide[1].
Lesen Sie auch
Left untreated, fascioliasis can result in considerable pain and discomfort, leading to poor quality of life and loss of productivity. The acute phase of the disease is manifested with fever, abdominal pain, nausea, diarrhea and eosinophilia. The disease later progresses to a latent phase with less symptoms and ultimately into a chronic or obstructive phase. In children, fascioliasis can be a serious infection with high fever, enlarged tender liver, and anemia.